ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy First-in-class examples of direct SHOC2 binders and modulators…
KBL Impact Partners calls on corporations to join its cross-sector leadership movement, blending corporate development and nonprofit innovation into a…